Indication: Advanced Solid Tumors
Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination with Budigalimab and/or Chemotherapy in Subjects with Advanced Solid Tumors
Sub-indication: Miscellaneous Malignancies
Study Type: Drug Study
Principal Investigator: Jaspreet Grewal, M.D.Norton Cancer Institute
Sponsor: Sponsor: Trishula Therapeutics, Inc.